Search company, investor...
Integral Molecular company logo

Integral Molecular

integralmolecular.com

Founded Year

2001

Stage

Loan | Alive

Total Raised

$1.18M

Last Raised

$680K | 3 yrs ago

About Integral Molecular

Integral Molecular develops technologies to enable the discovery and development of drugs that target integral membrane proteins, which are involved directly or indirectly in most major diseases, and comprise nearly half of all existing drug targets, including G protein-coupled receptors (GPCRs) and ion channels.

Headquarters Location

3711 Market Street Suite 900

Philadelphia, Pennsylvania, 19104,

United States

215-966-6061

Missing: Integral Molecular's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Integral Molecular's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Integral Molecular

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Integral Molecular is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Integral Molecular Patents

Integral Molecular has filed 11 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/13/2020

2/22/2022

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Antibodies

Grant

Application Date

2/13/2020

Grant Date

2/22/2022

Title

Related Topics

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Antibodies

Status

Grant

Latest Integral Molecular News

13:17 ET Integral Molecular Reveals Mechanism Underlying Exquisite Specificity of Claudin 6 Therapeutic Antibody Being Developed...

Jan 5, 2023

News provided by Share this article Share this article PHILADELPHIA, Jan. 5, 2023 /PRNewswire/ -- Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 (CLDN6) antibody CTIM-76  being developed for cancer therapy with Context Therapeutics. CLDN6 is a tumor-specific protein found in multiple solid tumors—including ovarian, endometrial, lung, gastric, and testicular—but absent from healthy adult tissues. Until now, its structural complexity and similarity to related proteins has hindered efforts to develop safe and selective therapeutics, with most CLDN6 antibody clinical trials being halted due to specificity-related safety issues. The similarity of the target to widely expressed Claudins 3, 4 and 9 means that non-specific binding could kill otherwise healthy tissues. Publication Details In their recent publication (Screnci et al., iScience December 2022), Integral Molecular scientists describe the isolation of highly specific CLDN6 antibodies that use a single atomic contact point centered around amino acid 156 to derive exquisite specificity. This interaction site allows the antibody to bind CLDN6 but not any of the other 24 claudin family members. Key findings include: Best-in-class specificity of CLDN6 antibodies compared to clinical benchmarks Unusual steric hindrance mechanism of the gamma carbon on Q156 discovered as critical for absolute specificity of antibodies for CLDN6 versus CLDN9 CLDN6 antibodies exhibited excellent developability "We are thrilled to be progressing high-specificity antibodies to safely target Claudin 6-positive tumors," said Ross Chambers, PhD, VP of Antibody Discovery at Integral Molecular. "The ability of our antibodies to interact specifically with Claudin 6 is extraordinary since the target and related proteins differ by just a few atoms at the binding site." Integral Molecular's MPS Antibody Discovery Platform is tailored to discover rare antibodies with maximal epitope diversity. Integral Molecular is co-developing CTIM-76 with Context Therapeutics to treat ovarian cancer and other solid tumors. CTIM-76 is a CLDN6xCD3 antibody that brings cytotoxic T cells into proximity with CLDN6-expressing tumor cells to initiate cell killing. Investigational New Drug (IND)-enabling studies are currently underway, and Context expects to submit an IND application for CTIM-76 to the U.S. Food and Drug Administration for first-in-human trials in the first quarter of 2024. About Integral Molecular Integral Molecular ( integralmolecular.com ) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses. Follow Integral Molecular on  LinkedIn Follow Integral Molecular on  Twitter Press Contact:

Integral Molecular Frequently Asked Questions (FAQ)

  • When was Integral Molecular founded?

    Integral Molecular was founded in 2001.

  • Where is Integral Molecular's headquarters?

    Integral Molecular's headquarters is located at 3711 Market Street, Philadelphia.

  • What is Integral Molecular's latest funding round?

    Integral Molecular's latest funding round is Loan.

  • How much did Integral Molecular raise?

    Integral Molecular raised a total of $1.18M.

  • Who are the investors of Integral Molecular?

    Investors of Integral Molecular include Paycheck Protection Program, U.S. Department of Health and Human Services and Science Center.

  • Who are Integral Molecular's competitors?

    Competitors of Integral Molecular include Arena Pharmaceuticals, Evotec SE, Hydra Biosciences, Relypsa, ChanTest and 10 more.

Compare Integral Molecular to Competitors

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

F
Functional Genetics

FGI, based in Rockville, Maryland, is developing drugs and diagnostics based on its genome-wide discovery and validation of genes and their roles in human disease. FGI has validated drug candidates for the treatment of infectious disease, drug resistant cancer and Alzheimer's disease.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

X
Xytis

Xytis is engaged in the development of central nervous systems drugs.

Metabolic Solutions Logo
Metabolic Solutions

Metabolic Solutions is working with a compound in the same class of drugs as two well-known diabetes medications -- Actos and Avandia which combined for sales of more than $5 billion in 2007. The firm says a potential drug Metabolic Solutions is testing now could be safer and more effective than Actos and Avandia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.